ArticlePloS one2014
Overall decrease in the susceptibility of Mycoplasma bovis to antimicrobials over the past 30 years in France.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Use of recombinant proteins for the diagnosis and prevention ofFrontiers in veterinary science · 2024Pooled it
- A randomised clinical trial of a metaphylactic treatment with tildipirosin for bovine respiratory disease in veal calves.BMC veterinary research · 2017Trial
- Application of multiplex PCR-based nanopore sequencing for rapid detection and surveillance of antimicrobial-resistantMicrobiology spectrum · 2026Article
- Dependence ofApplied and environmental microbiology · 2026Article
- Emergence of Novel Fluoroquinolone Resistance Mutations in Mycoplasma bovis, China, 2008-2023.Emerging infectious diseases · 2025Article
- The Pathogenomics of the RespiratoryPathogens (Basel, Switzerland) · 2025Article
- Exploring Metal Ions as Potential Antimicrobial Agents to Combat Future Drug Resistance inMicroorganisms · 2025Article
- Genomic analysis of the 2017 Aotearoa New Zealand outbreak ofFrontiers in microbiology · 2025Article
- Prevalence of bacteria involved in bovine respiratory disease in dairy heifers in Spain: influence of environmental factors.Frontiers in veterinary science · 2025Article
- Molecular detection of antimicrobial resistance in livestock mycoplasmas: current status and future prospects.Frontiers in veterinary science · 2025Review
- Genes required for survival and proliferation ofApplied and environmental microbiology · 2024Article
- A Set of Multiresistant Isolates ofPathogens (Basel, Switzerland) · 2024Article
- Identification of potential nucleomodulins ofFrontiers in microbiology · 2024Article
- Conserved Domains in Variable Surface Lipoproteins A-G ofVeterinary sciences · 2023Article
- Toward a Method for Harmonized Susceptibility Testing of Mycoplasma bovis by Broth Microdilution.Journal of clinical microbiology · 2023Article
- Drug Susceptibility Test and Analysis of Quinolone Resistance Genes inInfection and drug resistance · 2023Article
- Susceptibility of caprine mastitis pathogens to tildipirosin, gamithromycin, oxytetracycline, and danofloxacin: effect of serum on the in vitro potency of current macrolides.World journal of microbiology & biotechnology · 2022Article
- Article
- Genome-Wide Association Study of Nucleotide Variants Associated with Resistance to Nine Antimicrobials inMicroorganisms · 2022Article
- Prevalence ofFrontiers in veterinary science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma (M.) bovis is frequently implicated in respiratory diseases of young cattle worldwide. Today, to combat M. bovis in Europe, only antimicrobial therapy is available, but often fails, leading to important economical losses. The antimicrobial susceptibility of M. bovis is not covered by antimicrobial resistance surveillance networks. The objectives of this study were to identify resistances that were acquired over the last 30 years in France and to determine their prevalence within contemporary strains. The minimum inhibition concentration (MIC) values of 12 antimicrobials, considered active on M. bovis, were compared, using an agar dilution method, between 27 and 46 M. bovis isolates respectively obtained in 1978-1979 and in 2010-2012 from 73 distinct respiratory disease outbreaks in young cattle all over France. For eight antimicrobials, resistances were proven to be acquired over the period and expressed by all contemporary strains. The increase of the MIC value that inhibited 50% of the isolates (MIC50) was: i) substantial for tylosin, tilmicosin, tulathromycin and spectinomycin, from 2 to >64, 2 to >128, 16 to 128 and 4 to >64 µg/mL, respectively, ii) moderate for enrofloxacin, danofloxacin, marbofloxacin and oxytetracycline, from 0.25 to 0.5, 0.25 to 0.5, 0.5 to 1, 32 to >32 µg/mL, respectively. No differences were observed for gamithromycin, tildipirosin, florfenicol and valnemulin with MIC50 of 128, 128, 8, <0.03 µg/mL, respectively. If referring to breakpoint MIC values published for respiratory bovine pathogens, all contemporary isolates would be intermediate in vivo for fluoroquinolones and resistant to macrolides, oxytetracycline, spectinomycin and florfenicol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.